THYMIDYLATE SYNTHASE INHIBITION AFTER ADMINISTRATION OF FLUOROURACIL WITH OR WITHOUT LEUCOVORIN IN COLON-CANCER PATIENTS - IMPLICATIONS FOR TREATMENT WITH FLUOROURACIL

被引:204
作者
PETERS, GJ [1 ]
VANDERWILT, CL [1 ]
VANGROENINGEN, CJ [1 ]
SMID, K [1 ]
MEIJER, S [1 ]
PINEDO, HM [1 ]
机构
[1] FREE UNIV AMSTERDAM HOSP, DEPT SURG, 1081 HV AMSTERDAM, NETHERLANDS
关键词
D O I
10.1200/JCO.1994.12.10.2035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the time-dependence of fluorouracil (5FU)-induced thymidylate synthase (TS) inhibition in colon cancer patients, the effect of leucovorin (LV), and the relation to response. Patients and Methods: A 5FU injection (500 mg/m(2)) was given to 47 patients with advanced colorectal cancer; tumor biopsy specimens were obtained 1 to 72 hours after laparotomy. Eleven patients received LV (2-hour infusion of 500 mg/m(2)) with 5FU midinfusion; biopsies were obtained after 45 hours. TS inhibition was evaluated by comparing the number of total and free 5-fluoro-2'-deoxy-uridine-5'-monophosphate (UMP) (FdUMP) binding sites and the total and residual catalytic activity of TS. Results: The total catalytic TS activity varied from 0 to 621 pmol/h/mg protein and the total number of FdUMP binding sites varied from 0 to 976 fmol/mg protein. The residual catalytic TS activity after 2, 23, and 45 hours was 41%, 65%, and 74% of the total catalytic activity; the number of free FdUMP binding sites wets 12%, 27%, and 49% of the total number, respectively. LV enhanced TS inhibition after 45 hours; the residual catalytic activity decreased from 74% to 49%, and the number of free FdUMP binding sites from 49% ta 24%. Eleven of 19 patients treated with hepatic arteriol infusion of 5FU had a partial response (PR). in the nonresponding patients, total TS activity was significantly higher (P < .05) than in responding patients. A high TS activity with a poor inhibition correlated with no response. Conclusion: Residual and total TS activity are predictive for response to 5FU. The findings may be applicable for treatment of patients with advanced disease and TS should be evaluated as a prognostic factor in adjuvant chemotherapy studies.
引用
收藏
页码:2035 / 2042
页数:8
相关论文
共 38 条
[1]  
ASCHELE C, 1992, CANCER RES, V52, P1855
[2]  
BAPAT AR, 1983, J BIOL CHEM, V258, P4130
[3]  
BERGER SH, 1988, MOL PHARMACOL, V34, P480
[4]  
BERGER SH, 1985, MOL PHARMACOL, V28, P461
[5]  
CHU E, 1993, MOL PHARMACOL, V43, P527
[6]  
CLARK JL, 1987, CANCER TREAT REP, V71, P261
[7]   THYMIDYLATE SYNTHETASE - TARGET ENZYME IN CANCER CHEMOTHERAPY [J].
DANENBERG, PV .
BIOCHIMICA ET BIOPHYSICA ACTA, 1977, 473 (02) :73-92
[8]   A METHOD FOR THE DETERMINATION OF TOTAL, FREE, AND 5-FLUORODEOXYURIDYLATE-BOUND THYMIDYLATE SYNTHASE IN CELL-EXTRACTS [J].
FERNANDES, DJ ;
CRANFORD, SK .
ANALYTICAL BIOCHEMISTRY, 1984, 142 (02) :378-385
[9]  
FREEMANTLE S J, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P360
[10]  
HORIKOSHI T, 1992, CANCER RES, V52, P108